Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


People In Brief

This article was originally published in The Gray Sheet

Executive Summary

Northstar names CEO: Chief Operating Officer John Bowers assumes the top spot at Northstar Neuroscience June 29. Prior to joining Northstar in 2004, Bowers served 10 years at Guidant in marketing, business development and sales management, for a time leading the marketing and business development efforts for the company's drug-eluting stent business now owned by Abbott. He replaces Alan Levy, who will become chairman of the board. The firm is on track to submit a PMA by early next year for its cortical stimulation device for hand and arm rehabilitation in stroke victims. Clinical trials are ongoing for the device's use in treating stroke-related aphasia, tinnitus and treatment-resistant depression (1"The Gray Sheet" Oct. 9, 2006, In Brief). On April 26, Northstar reported a net loss of $4.3 million for the first quarter of 2007...

Related Content

ACC In Brief
Abiomed Submits 510(k) For Impella Ventricular Assist Device
Northstar neurostim depression study



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts